{"id":"np101","safety":{"commonSideEffects":[{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Somnolence"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Paresthesia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"NP101 selectively binds to 5-HT1F receptors on trigeminal nerve terminals and cranial blood vessels, leading to vasoconstriction and suppression of pain-signaling neuropeptide release. This mechanism is distinct from traditional triptans, which target multiple serotonin receptors, potentially offering improved tolerability and efficacy in acute migraine treatment.","oneSentence":"NP101 is a selective serotonin 5-HT1F receptor agonist that reduces migraine pain by constricting cranial blood vessels and inhibiting neuropeptide release.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:23:24.364Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute migraine with or without aura"}]},"trialDetails":[{"nctId":"NCT06563375","phase":"PHASE1","title":"Phase 1 Dose Escalation and Dose Expansion Trial of NP-101 in Patients With Solid Tumors","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-03-05","conditions":"Solid Tumor","enrollment":35},{"nctId":"NCT06217094","phase":"PHASE1","title":"Study of NP-101 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Undergoing Y-90 Treatment","status":"WITHDRAWN","sponsor":"University of Florida","startDate":"2026-02","conditions":"Hepatocellular Carcinoma","enrollment":""},{"nctId":"NCT05262556","phase":"PHASE1","title":"NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amr Mohamed MD","startDate":"2022-12-15","conditions":"Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Neoplasm, Neuroendocrine Carcinoma","enrollment":15},{"nctId":"NCT05785390","phase":"PHASE2","title":"Study of the Safety, Tolerability and Efficacy of NP-101 in Treating High Risk Participants Who Are Covid-19 Positive.","status":"TERMINATED","sponsor":"Novatek Pharmaceuticals","startDate":"2023-02-22","conditions":"COVID-19","enrollment":170},{"nctId":"NCT01381796","phase":"PHASE1","title":"Compare PK and Bioavailability of 2 NP101 Patches With Oral Imitrex in Healthy Adults","status":"COMPLETED","sponsor":"NuPathe Inc.","startDate":"2009-12","conditions":"Compare Bioequivalence Patches Previously Used in the NP101-007 Study","enrollment":63},{"nctId":"NCT00806546","phase":"PHASE3","title":"An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months","status":"COMPLETED","sponsor":"NuPathe Inc.","startDate":"2009-02","conditions":"Migraine Disorders","enrollment":514},{"nctId":"NCT00792103","phase":"PHASE3","title":"An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months","status":"COMPLETED","sponsor":"NuPathe Inc.","startDate":"2009-01","conditions":"Migraine Disorders","enrollment":198},{"nctId":"NCT00724815","phase":"PHASE3","title":"The Efficacy and Tolerability of NP101 Patch in the Treatment of Acute Migraine","status":"COMPLETED","sponsor":"NuPathe Inc.","startDate":"2009-01","conditions":"Migraine Disorders","enrollment":530},{"nctId":"NCT00720018","phase":"PHASE1","title":"Phase I Open Label Single-Dose Study to Compare the Pharmacokinetics of NP101 Healthy Volunteers","status":"COMPLETED","sponsor":"NuPathe Inc.","startDate":"2008-06","conditions":"Migraine Disorders","enrollment":4},{"nctId":"NCT00546650","phase":"PHASE1","title":"Phase I Study to Compare NP101(Sumatriptan Iontophoretic Transdermal Patch) With Three Formulations of Imitrex®","status":"COMPLETED","sponsor":"NuPathe Inc.","startDate":"2007-11","conditions":"Healthy","enrollment":25},{"nctId":"NCT00723983","phase":"PHASE1","title":"Phase I, Open Label, Single-Dose, Four Way Crossover Study to Compare the PK of NP101 With Oral Imitrex® (50mg) in Migraine Subjects During an Acute Migraine Attack and During a Non-Migraine Period","status":"COMPLETED","sponsor":"NuPathe Inc.","startDate":"2008-11","conditions":"Migraine Disorders","enrollment":23}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"NP101","genericName":"NP101","companyName":"NuPathe Inc.","companyId":"nupathe-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"NP101 is a selective serotonin 5-HT1F receptor agonist that reduces migraine pain by constricting cranial blood vessels and inhibiting neuropeptide release. Used for Acute migraine with or without aura.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}